Publication: Correlación de la pérdida ósea periimplantaria respecto a la densidad mineral ósea sistémica en pacientes postmenopáusicas
Loading...
Official URL
Full text at PDC
Publication Date
2013
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Citations
Exportar
Abstract
Description
UCM subjects
Unesco subjects
Keywords
Citation
1. Amorim MAL, Takayama L, Jorgetti V, Pereira RMR. Comparative study of axial and femoral bone mineral density and parameters of mandibular bone quality in patients receiving dental implants.International Osteoporosis Foundation and National Osteoporosis Foundation.2007; 18:703 –709.
2. Holahan C, Koka S, Kennel K, Weaver A, Assad D, Regennitter F, Kademani D. Effect of Osteoporotic Status on the Survival of Titanium Dental Implants. The International Journal of Oral and Maxillofacial Implants.2008; 23:905-910.
3. Kong YY, Penninger JM.Molecular control of bone remodelling and osteoporosis. Exp Gerontol.2000; 35: 947-56.
4. Lethaby A, Farquhar C, Sarkis A, Roberts H, Jepson R, Barlow D. Terapia de reemplazo hormonal en mujeres postmenopáusicas: hiperplasia endometrial y sangrado irregular (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2008 Número. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com. (Traducida de The Cochrane Library.2008 Issue 3. Chichester, UK: John Wiley y Sons, Ltd.).
5. López Morales Y, Marco Martínez F. (2010). Osteoporosis e implantes en el hueso osteoporótico en Sociedad Española de Cirugía Ortopédica y Traumatología, eds. Manual de Cirugía Ortopédica y Traumatología. Madrid: Editorial Médica Panamericana, S.A., pp. 185-188.
6. WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Osteoporosis Int. 1994; 4:368-81.
7. Yang J, Farnell D, Devlin H, Horner K, Graham J. The effect of ovariectomy on mandibular cortical thickness in the rat. J Dent.2005; 33:123-9.
8. White SC, Taguchi A, Kao D, Wu S, Service SK, Yoon D, et al. Clinical and panoramic predictors of femur bone mineral density. Osteoporos Int. 2005; 16:339-46.
9. Bodic F, Hamel L, Lerouxel E, Basle MJ, Chappard D. Bone loss and teeth. Joint Bone Spine. 2005; 72:215-21.
10. Marco F, Milena F, Gianluca G, Vittoria O. Peri-implant osteogenesis in health and osteoporosis. Micron. 2005; 36:630-44.
11. Fini M, Giavaresi G, Torricelli P, Borsari V, Giardino R, Nicolini A, et al. Osteoporosis and biomaterial osteointegration. Biomed Pharmacother. 2004; 58:487-93.
12. Duarte PM, Conclaves PF, Casati MZ, Sallum EA, Nociti FH Jr. Age-related and surgically induced estrogen deficiencies may differently affect bone around titanium implants in rats.J Periodontol. 2005; 76(9):1496-501.
13. Fujimoto T, Niimi A, Sawai T, Ueda M. Effects of steroid-induced osteoporosis on osseointegration of titanium implants. Int J Oral Maxillofac Implants. 1998; 13:183-9. 14. Mori H, Manabe M, Kurachi Y, Nagumo M. Osseointegration of dental implants in rabbit bone with low mineral density.J Oral Maxillofac Surg. 1997; 55:351-61.
15. Lugero GG, de Falco Caparbo V, Guzzo ML, Konig B Jr, Jorgetti V. Histomorphometric evaluation of titanium implants in osteoporotic rabbits. Implant Dent. 2000; 9(4):303-9.
16. Jaffin RA, Berman CL. The excessive loss of Branemark fixture in type IV bone: a 5-year analysis. J Periodontol. 1991; 62:2–4.
17. Von Wowern N, Klausen B, Kollerup G. Osteoporosis: a risk factor in periodontal disease. J Periodontol. 1994; 65:1134 –1138.
18. Wakley GK, Baylink DJ. Systemic influences on the bone response to dental and orthopedic implants. J Oral Implantol. 1988; 14(3):285–311.
19. Baron R. (2003).Anatomy and Biology of Bone Matrix and Cellular Elements. Chapter 1.General Principles of Bone Biology.Primer on the metabolic bone diseases and disorders of mineral research, (5th ed). Washington, DC.
20. Balderrama R. 2002. La osteoporosis. http://www.monografias.com/trabajos11/osteop/osteop.shtml
21. Friedenstein AJ. Precursor cells of mechanocytes. Int Rev Cytol 1976; 47: 327-59.
22. Harada S, Rodan GA. Control of osteoblast function and regulation of bone mass. Nature 2003; 423: 349-55.
23. Compston JE.Sex Steroids and Bone. Physiol Rev. 2001; 81:419-47.
24. Steinberg TH, Civitelli, Geist ST, Robertson AJ, Hick E, Veenstra RD, Wang H-Z, Warlow PM, Westphale EM, Laing JG, Beyer EC. Connexin43 and connexin45 form gap junctions with different molecular permeabilities in osteoblastic cells. EMBO J. 1994; 13(4):744-50.
25. Yamaguchi A, Komori T, Suda T. Regulation of osteoblast differentiation mediated by Bone Morphogenetic Proteins, Hedgehogs, and Cbfa1. Endocr Rev. 2000; 21(4): 393-411.
26. Fernández-Tresguerres-Hernández-Gil I, Alobera-Gracia MA, del Canto- Pingarrón M, Blanco-Jerez L. Physiological bases of bone regeneration II.The remodelling process. Med Oral Patol Oral Cir Bucal. 2006; 11(2): E151-7.
27. Prieto S. Fisiología del hueso. En: Tresguerres JAF, ed. Fisiología humana. Madrid: McGraw-Hill Interamericana de España. 1992; p. 1032-45.
28. Aubin JE, Liu F.The osteoblasts lineage.Principles of Bone Biology.San Diego, California, 1996 Academic Press.
29. Lanyon L. Osteocytes, strain detection, bone remodeling and remodeling. Calcified Tissue Int. 1993; 53 Suppl1:S102-7.
30. Winkler DG, Sutherland MS, Ojala E, Turcott E, Geoghegan JC, Shpektor D, Skonier JE, Yu C, Latham JA. Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins. J Biol Chem. 2005; 280(4)2498-502. Epub 2004 Nov 12.
31. Sutherland MK, Geoghegan JC, Yu C, Turcott E, Skonier JE, Winkler DG, Latham JA. Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation.Bone. 2004; 35(4):828-35.
32. Mundy GR. Cytokines and growth factors in the regulation of bone remodeling. J Bone Miner Res. 1993; 8 Suppl 2:S505-10.
33. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burguess TL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclasts differentiation and activation cell. 1998; 93: 165-76.
34. Boyle WJ, Simonet WS, Lacey DL.Osteoclast differentiation and activation. Nature.2003; 423:337-342.
35. Young MF. Bone matrix proteins: more than markers. Calcif Tissue Int. 2003; 72(1): 2-4.
36. Robey PG, Fedarko NS, Hefferan TE, Bianco P, Vetter UK, Grzesik W et al. Structure and molecular regulation of bone matrix proteins. J Bone Miner Res. 1993; Suppl2: S 483 -7.
37. Tresguerres IF. Influencia de la hormona de crecimiento en la osteointegración. Tesis Doctoral. Facultad de Odontología de la Universidad Complutense de Madrid, 1999.
38. Posner AS.The mineral of bone. Clin Orthop.1985; 200:87-99.
39. Roberts E.Bone Tissue Interface.J Dental Educat.1988; 52:804-9.
40. Davies JE, Hosseini MM. Histodinamics of endosseous would healing.Bone Engineering. Toronto 2000.
41. Serrano S, Mariñoso ML. (1990). Bases histológicas de la histomorfometría ósea. Barcelona.
42. Lind M, Deleuran B, Thestrup-Pedersen K, Soballe K, Eriksen EF, Bunger C.Chemotaxis of human osteoblasts.Effects of osteotropic growth factors. APMIS. 1995; 103(2): 140-6.
43. Pocock NA, Eisman JA, Hopper JL, Yeates MG, Sambrock PN, Ebery S.Genetic determinants of bone mass in adults. J Clin Invest. 1987; 80:706-10.
44. Morey ER, Baylink JJ.Inhibition of bone formation during space flight.Science. 1978; 201: 1138-41.
45. Trueta J.The role of blood vessels in osteogenesis. J Bone Joint Surg Br. 1963; 45: 402.
46. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL. Estrogen stimulates gene expresion and protein production of osteoprotegerin in human osteoblastic cells.Endocrinology. 1999; 140: 4367-70.
47. Cohick WS, Clemmons DR.The insulin-like growth factors.Annu Rev Physiol. 1993; 55: 131-53.
48. Hill PA, Reynolds JJ, Meikle MC. Osteoblasts mediate insulin-like growth factor-I and -II stimulation of osteoclasts formation and function.Endocrinology 1995; 136: 124-31.
49. Mohan S, Baylink DJ. Bone growth factors.Clin Orthop. 1991; 263: 30-48.
50. Baylink DJ, Finkelman RD, Mohan S. Growth factors to stimulate bone formation. J Bone Miner Res. 1993; 8(2): 565-72.
51.Nash TJ, Howlett CR, Martin C, Steele J, Johnson KA, Hicklin DJ.Effects of platelet-derived growth factor on tibial osteotomies in rabbits.Bone. 1994; 15:203-8.
52. Marie PJ.Fibroblast growth factor signaling controlling osteoblast differentiation. Gene.2003; 316: 23-32.
53. Horowitz M. Matrix proteins versus cytokines in the regulation of osteoblasts function and bone formation. Calcif Tissue Int. 2003; 72: 5-7.
54. Knothe Tate ML, Adamson JR, Tami AE, Bauer TW.The osteocyte. Int J Biochem Cell Biol. 2004; 36(1): 1-8.
55. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis preventions, diagnosis and therapy. JAMA. 2001; 285(6):785-95.
56. Palacios, S; Hernández, K. Comprender la Osteoporosis. Barcelona: Amat, S.L. 2009. p. 7-159.
57. Romanillos JO, Rodríguez EC. Últimas investigaciones ortopédicas sobre osteoporosis y sus posibles aplicaciones prácticas. En: Rodríguez Merchan EC, Ortega Andreu M, Alonso Carro G, eds. Fracturas osteoporóticas. Prevención y tratamiento. Madrid: Médica Panamericana. 2003; p. 167-97.
58. Ettinger B, Genant HK, Cann C. Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med. 1985; 102(3): 319–324.
59.Vinco L, Prallet B, Chappard D, Pallot-Prades B, Pupier R, Alexandre C. Contributions of chronological age, age at menarche and menopause and of anthropometric parameters to axial and peripheral bone densities. Osteoporosis Int. 1992: 2: 153–158.
60. Kellie SE, Body JA.Sex-specific and race-specific hip fracture rates. Am J Public Health. 1990: 80: 326–330.
61. Cooper C, Melton LJ III.Magnitude and impact of osteoporosis and fractures. In: Marcus R, Feldman D, Kelsey J, ed. Osteoporosis. San Diego: Academic Press.1996; 419– 434.
62. Holbrook TL, Barrett-Connor E, Wingard DL. Dietary calcium and risk of hip fracture: 14-year prospective population study. Lancet. 1988; 2: 1046–1049.
63. Hemenway D, Colditz GA, Willett WC, Stampfer MJ, Speizer FE. Fractures and lifestyle: Effect of cigarette smoking, alcohol intake, and relative weight on the risk of hip and forearm fractures in middle-aged women. Am J Public Health. 1988; 78(12): 1154–1158.
64. MMelton III LJ, Atkinson EJ, O´Fallon WH, Wahner HW, Riggs BL. Long term fracture risk prediction with bone mineral measurements made at various skeletal sites. J Bone Miner Res. 1991; 6 (Supl 1) S136).
65. Cobo T, Hernández A, Torrijos A. Técnicas para la valoración de la masa ósea en la osteoporosis. En: Rodríguez Merchan EC, Ortega Andreu M, Alonso Carro G, eds. Fracturas osteoporóticas. Prevención y tratamiento. Madrid: Médica Panamericana. 2003; p. 31- 40.
66. Cullum ID, Ell PJ, Ryder JP. Xray dual photon absorptiometry: a new method for the measurement of bone density.Br J Radiol.1989; 62: 587-92.
67. Otomo-Corgel J. Implants and oral bisphosphonates: risk business. J Periodontol. 2007; 78(3): 373-6.
68. Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, Kavanagh KL, Triffitt JT, Lundy MW, Phipps RJ, Barnett BL, Coxon FP, Rogers MJ, Watts NB, Ebertino FH. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. An N Y Acad Sci. 2007; 1117: 209-57.
69.Whyte MD, Wincer D, Clements KL, McAlister WH, Mumm S. "Bisphosphonate-induced osteopetrosis. N Engl J Med. 2003; 349(5): 457-63.
70. Ponte Fernández N, Estefanía Fresco R, Aguirre-Urizar JM. Bifosfonatos y patología Oral I. Aspectos generales y preventivos. Med Oral Patol Oral Cir Bucal. 2006; 11(6): E456-61.
71. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-Induced Exposed Bone (Osteonecrosis/Osteopetrosis) of the Jaws: Risk Factors, Recognition, Prevention, and Treatment. J Oral Maxillofac Surg. 2005; 63(11): 1567–1575.
72. Assael LA. Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of the risks, and preventive strategies. J Oral Maxillofac Surg. 2009; 67(5): 35-43.
73. Grewal VS, Fayans EP. Bisphosphonate-associated osteonecrosis: a clinician´s reference to patient management. Todays FDA. 2008; 20(8): 38-46.
74. Panel de expertos de la Sociedad Española de Reumatología, 2003, Orozco 2001. Documento 2003 de la Sociedad Española de Reumatología sobre la osteoporosis postmenopáusica.Rev Esp Reumatol. 2003;30:565-71.Descargado:http://www.doyma.es
75. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C, the Osteoporosis Methodology Group, and the Osteoporosis Research Advisory Group.Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev. 2002; 23(4):570-8.
76. Albrektsson T, Zarb GA. Current interpretations of the osseointegrated response: clinical significance. Int J Prosthodont. 1993; 6(2): 95-105.
77. Schnitman PA, Schulman LB. Recommendation of the consensus development conference of dental implants. Dental implants: benefit and risk. An NIH-Harvard Consensus Development Conference Pub no.81-1531.Bethesda: Department of Health and Human Services, National Institutes of Health. 1980.
78. Albrektsson T, Zarb GA, Worthington P, Eriksson AR. The long-term efficacy of currently used dental implants: a review and proposed criteria of success. Int J Oral Maxillofac Implants. 1986; 1:11-25.
79. Lekholm U, Gunne J, Henry P, Higuchi K, Linden U, Bergstrom C, Van Steenberghe D.: Survival of the Branemark Implant in partially. Edentolous jaws: a 10-year prospective multicenter study. Int J Oral and Maxillofac Implants.1999; 14: 639-645.
80. Esposito M, Thomsen P, Ericson LE, Lekholm U.: Histopatologic observations on early oral implant failures. Int J Oral Maxillofac Implants.1999; 14: 798-810.
81. Esposito M, Hirsh J-M, Lekholm U, Thomsen P.: Biological factors contributing to failures of ossointegrated oral implants (I).Success criteria and epidemiology. Eur J Sci. 1998; 106:527 -51.
82. Hutton JE, Heath MR, Chai JY, Harnett J, Jemt T, Johns RB, McKenna S, McNamara DC, van Steenberghe D, Taylor R, et. Factors related to success and failure rates at 3-year follow-up in a multicenter study of overdentures supported by Brånemark implants. Int J Oral Maxillofac Implants. 1995 Jan-Feb; 10 (1):33-42.
83. Bahat O. Brånemark system implants in the posterior maxilla: clinical study of 660 implants followed for 5 to 12 years. Int J Oral Maxillofac Implants. 2000 Sep-Oct; 15 (5):646-53.
84. Friberg B, Ekestubbe A, Mellström D, Sennerby L Brånemark implants and osteoporosis: a clinical exploratory study. Clin Implant Dent Relat Res. 2001; 3(1):50-6.
85. Tawil G, Younan R Clinical evaluation of short, machined-surface implant followed for 12 to 92 months. Int J Oral Maxillofac Implants. 2003 Nov-Dec; 18(6):894-901.
86. Kaplan EL, Meier P. No parametric estimation from incomplete observations. Amer. Statist. Ass.1958; 53:457-481.
87. Cutler SJ, Ederer F. Maximum utilization of the life table method in analyzing survival. J. chron. Dis.1958; 8: 699-712.
88. Mombelli A y Mericske -Stern R. Microbiological features of stable osseointegrated implants used as abutments for overdentures. Clinical Oral Implants Research.1990; 1:1-7.
89. Everitt, B. S.The Analysis of Contingency Tables.Chapman & Hall.Second Edition. 1992.
90. Ferrán Aranaz, M. SPSS para Windows. Programación y Análisis Estadístico. Mc Graw Hill. 1996.
91. SPSS.SPSS Statistics 19.0 Command Syntax Reference.SPSS Inc.2010.
92. Kribbs, P. Comparison of mandibular bone in normal and osteoporotic women.J Prostheet Dent. 1990; 63:218-222.
93. Nedelman, C. & Bernick, S. The significance of age changes in human alveolar mucosa and bone. J Prosthet Dent. 1978; 39 (5):495.
94. Cohen, J., & Cohen, P. (1983).Applied multiple regression/correlation analysis for the behavioral sciences. Hillsdale, NJ: Lawrence Erlbaum Associates, Inc.
95. Lindh C, Obrant K, Petersson A. Maxillary bone mineral density and its relationship to the bone mineral density of the lumbar spine and hip.Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004; 98:102-9.
96. Southard KA, Southard TE, Schlechte JA, Meis PA.The relationship between the density of the alveolar process and that of post-cranial bone. J Dent Res.2000; 79:964-9.
97. Taguchi A, Tanimoto K, Suei Y, Ohtsuka M, Hollender LG. Relationship between bone mineral density and tooth loss in elderly Japanese women.Dentomaxillofac Radiol. 1999; 28:219–223.
98. Von Wowern N, Storm TL, Olgaard K. Bone mineral content by photon absorptiometry of the mandible compared with that of the forearm and the lumbar spine. Calcif Tissue Int. 1988; 42:157-61.
99. Valerie A, Vehemente BS, Chuang S, Daher S, Muftu A, Dodson T. Risk factors affecting dental implant survival. Journal of Oral Implantology. 2002. 28: 74-81.
100. Rivero M, Del Río J, Martínez J.A. y Celemín A (2009). Tabaco e Implantes. Preguntas y respuestas en Implantoprótesis (pp. 83-85). Madrid.
101. Bergstron J. El hábito de fumar y el cálculo supragingival. J. Clin. Periodontal. 1999 Aug.; 26 (8): 541-47.
102. Norderyd O. El riesgo de la enfermedad periodontal severa en una población de adultos sueca. J. Clin. Periodontal. 1998 dic. ; 25(12): 1022-28.
103. Ichikawa T, Hirota K, Miyake Y, Matsumoto N. In vitro adherence of Streptococcus constellatus to dense hydroxyapatite and titanium. J Oral Rehabil. 1998; 25:125-7.
104. Berglundh T, Persson L, Klinge B: A systematic review of the incidence of biological and technical complications in implant dentistry reported in prospective longitudinal studies of at least 5 years. J Clin Periodontol. 2002; 29(Suppl. 3): 197–212.
105. Vere J, Bhakta S, Patel R. Prosthodontic complications associated with implant retained crowns and bridgework: a review of the literature. Br Dent J. 2012 Mar 23; 212(6):267-72.
106.Quinteros M, Delgado E, Sánchez M.A., Berini L, Gay C. Estudio microbiológico de la periimplantitis presentación de 9 casos clínicos. Av Periodon Implanto.2000; 2:137-150.
107. Alsaadi G, Quirynen M, Komárek A, Van Steenberghe D. Impact of local and systemic factors on the incidence of oral implant failures, up to abutment connection.J Clin Periodontol.2007; 34:610-7.
108. Alsaadi G, Quirynen, Michiles K, Teughels W, Komárek A, van Steenberghe D. Impact of local and systemic factors on the incidence of oral implant failures, up to abutment connection with modified surface oral implants. J Clin Periodontol. 2008; 35:51-7.
109. Kronström M, Svensson B, Erickson E, Houston L, Braham P, Persson GR. Humoral immunity host factors in subjects with failing or successful titanium dental implants. J Clin Periodontol. 2000; 27:875–882.
110. Sverzut AT, Stabile GA, de Moraes M, Mazzonetto R, Moreira RW.The influence of tobacco on early dental implant failure. Int J Oral Maxillofac Surg.2008; 66:1004-9.
111. Albrektsson T, Zarb GA.: Current interpretations of the osseointegrated response: clinical significance. Int J Prosthodont. 1993; 6(2): 95-105.
112. Holahan CM, Koka S, Kennel KA, Weaver AL, Assad DA, Regennitter FJ, Kademani D. Int J Oral Maxillofac Implants. 2008; 23:905-10.
113. Roos-Jansa°ker A-M, Lindahl C, Renvert H, Renvert S. Nine- to fourteen-year follow-up of implant treatment. Part I: implant loss and associations to various factors. J Clin Periodontol. 2006; 33: 283–289.
114. Kan JY, Rungcharassaeng K, Lozada J. Inmediate placement and provisionalization of maxillary anterior single implants: 1-year prospective study. Int J Oral Maxillofac Implants. 2003;18: 31-9.